Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Plasma cell 3Other hematologic neoplasm 3Thoracic 2Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Nasopharyngeal Carcinoma 1

Interventions

Cisplatin 144Radiotherapy 71Fluorouracil 50Radiotherapy, Intensity-Modulated 45Docetaxel 39Gemcitabine 38Cetuximab 38Carboplatin 31pembrolizumab 25Capecitabine 22Drug Therapy 17toripalimab 14Paclitaxel 14camrelizumab 10Surgical Procedures, Operative 10Nivolumab 10Chemoradiotherapy 10nimotuzumab 9Radiation 9Neoadjuvant Therapy 8Methotrexate 8Magnetic Resonance Spectroscopy 8Chemotherapy, Adjuvant 8nedaplatin 7Thyrotropin Alfa 7Platinum 7tislelizumab 6spartalizumab 6Standard of Care 6Specimen Handling 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Maintenance × Head & Neck × Clear all
NCT06277050 2026-05-15

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Jiangxi Provincial Cancer Hospital

Phase 3 Recruiting
264 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡